SANT-2Inhibitor of Hedgehog (Hh) signaling; antagonizes smoothened activity CAS# 329196-48-7 |
- Cyclopamine
Catalog No.:BCN2964
CAS No.:4449-51-8
- Purmorphamine
Catalog No.:BCC3641
CAS No.:483367-10-8
- GANT61
Catalog No.:BCC1090
CAS No.:500579-04-4
- GANT 58
Catalog No.:BCC1587
CAS No.:64048-12-0
- GDC-0449 (Vismodegib)
Catalog No.:BCC1285
CAS No.:879085-55-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 329196-48-7 | SDF | Download SDF |
PubChem ID | 1367095 | Appearance | Powder |
Formula | C26H26ClN3O4 | M.Wt | 479.96 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
Chemical Name | N-[3-(1H-benzimidazol-2-yl)-4-chlorophenyl]-3,4,5-triethoxybenzamide | ||
SMILES | CCOC1=CC(=CC(=C1OCC)OCC)C(=O)NC2=CC(=C(C=C2)Cl)C3=NC4=CC=CC=C4N3 | ||
Standard InChIKey | VQOJFGFKIVFMDH-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C26H26ClN3O4/c1-4-32-22-13-16(14-23(33-5-2)24(22)34-6-3)26(31)28-17-11-12-19(27)18(15-17)25-29-20-9-7-8-10-21(20)30-25/h7-15H,4-6H2,1-3H3,(H,28,31)(H,29,30) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Inhibitor of Sonic hedgehog (Shh) signaling; antagonizes smoothened receptor activity (KD = 12 nM). Displays allosteric binding characteristics similar to SANT-1. Displaces smo-[3H]SAG-1.3 and -[3H]Cyclopamine binding (Ki values are 7.8 nM and 8.4 nM respectively). |
SANT-2 Dilution Calculator
SANT-2 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0835 mL | 10.4175 mL | 20.8351 mL | 41.6701 mL | 52.0877 mL |
5 mM | 0.4167 mL | 2.0835 mL | 4.167 mL | 8.334 mL | 10.4175 mL |
10 mM | 0.2084 mL | 1.0418 mL | 2.0835 mL | 4.167 mL | 5.2088 mL |
50 mM | 0.0417 mL | 0.2084 mL | 0.4167 mL | 0.8334 mL | 1.0418 mL |
100 mM | 0.0208 mL | 0.1042 mL | 0.2084 mL | 0.4167 mL | 0.5209 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Inhibitor of Sonic hedgehog (Shh) signaling; antagonizes smoothened receptor activity (KD = 12 nM).
- Withanolide A
Catalog No.:BCN8010
CAS No.:32911-62-9
- PMSF
Catalog No.:BCC1229
CAS No.:329-98-6
- DL-Adrenaline
Catalog No.:BCC4318
CAS No.:329-65-7
- Norepinephrine hydrochloride
Catalog No.:BCC5133
CAS No.:329-56-6
- 4E1RCat
Catalog No.:BCC5338
CAS No.:328998-25-0
- C646
Catalog No.:BCC4546
CAS No.:328968-36-1
- pep2-SVKI
Catalog No.:BCC5784
CAS No.:328944-75-8
- Tildipirosin
Catalog No.:BCC5478
CAS No.:328898-40-4
- De-O-methyllasiodiplodin
Catalog No.:BCN7187
CAS No.:32885-82-8
- Lasiodiplodin
Catalog No.:BCN4770
CAS No.:32885-81-7
- Cajanin
Catalog No.:BCN5249
CAS No.:32884-36-9
- Benzylamine hydrochloride
Catalog No.:BCN6908
CAS No.:3287-99-8
- Quetiapine hydroxy impurity
Catalog No.:BCN5340
CAS No.:329216-67-3
- Boc-His(Trt)-OH
Catalog No.:BCC3403
CAS No.:32926-43-5
- Sanggenol L
Catalog No.:BCN3692
CAS No.:329319-20-2
- 7-O-Methylaloeresin A
Catalog No.:BCN2849
CAS No.:329361-25-3
- FPR A14
Catalog No.:BCC7498
CAS No.:329691-12-5
- Pinoresinol diacetate
Catalog No.:BCN5250
CAS No.:32971-25-8
- 2-Acetyl-3-ethylpyrazine
Catalog No.:BCC8512
CAS No.:32974-92-8
- Cinaciguat
Catalog No.:BCC1484
CAS No.:329773-35-5
- Methyl (2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoate
Catalog No.:BCN8520
CAS No.:32981-85-4
- 10-Deacetylbaccatin III
Catalog No.:BCN5251
CAS No.:32981-86-5
- Tobramycin
Catalog No.:BCC4739
CAS No.:32986-56-4
- Viomycin
Catalog No.:BCC3930
CAS No.:32988-50-4
Synthesis and biological evaluation of SANT-2 and analogues as inhibitors of the hedgehog signaling pathway.[Pubmed:19541490]
Bioorg Med Chem. 2009 Jul 15;17(14):4943-54.
Hedgehog (Hh) signaling plays an important role in cell signaling of embryonic development and adult tissue homeostasis. In vertebrates, the hh gene encodes three different unique proteins: sonic hedgehog (Shh), desert hedgehog (Dhh) and indian hedgehog (Ihh). Disruption of the Hh signaling pathway leads to severe disorders in the development of vertebrates whereas aberrant activation of the Hh pathway has been associated with several malignancies including Gorlin syndrome (a disorder predisposing to basal cell carcinoma, medulloblastoma and rhabdomyosarcoma), prostate, pancreatic and breast cancers. In vivo evidence suggests the antagonism of excessive Hh signaling provides a route to unique mechanism-based anti-cancer therapies. Recently the small molecule SANT-2 was identified as a potent antagonist of Hh-signaling pathway. Here, we describe the synthesis, SAR studies as well as biological evaluation of SANT-2 and its analogues. Fifteen SANT-2 derivatives were synthesized and analyzed for their interference with the expression of the Hh target gene Gli1 in a reporter gene assay. By comparison of structure and activity important molecular descriptors for Gli inhibition could be identified. Furthermore we identified derivative TC-132 that was slightly more potent than the parent compound SANT-2. Selected compounds were tested for Hh related teratogenic effects in the small teleost model medaka. Albeit Gli expression has indicated a 16-fold higher Hh-inhibiting activity than observed for the plant alkaloid cyclopamine, none of the tested compounds were able to induce the cyclopamine-specific phenotype in the medaka assay.
Evidence for allosteric interactions of antagonist binding to the smoothened receptor.[Pubmed:19304771]
J Pharmacol Exp Ther. 2009 Jun;329(3):995-1005.
The Smoothened receptor (Smo) mediates hedgehog (Hh) signaling critical for development, cell growth, and migration, as well as stem cell maintenance. Aberrant Hh signaling pathway activation has been implicated in a variety of cancers, and small-molecule antagonists of Smo have entered human clinical trials for the treatment of cancer. Here, we report the biochemical characterization of allosteric interactions of agonists and antagonists for Smo. Binding of two radioligands, [(3)H]3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-{[3-(4-pyridinyl)-phenyl]met hyl}-1-benzothiophene-2-carboxamide (SAG-1.3) (agonist) and [(3)H]cyclopamine (antagonist), was characterized using human Smo expressed in human embryonic kidney 293F membranes. We observed full displacement of [(3)H]cyclopamine by all Smo agonist and antagonist ligands examined. N-[(1E)-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-yl)methylidene]-4-(phenylmethyl)-1-pi perazinamine (SANT-1), an antagonist, did not fully inhibit the binding of [(3)H]SAG-1.3. In a functional cell-based beta-lactamase reporter gene assay, SANT-1 and N-[3-(1H-benzimidazol-2-yl)-4-chlorophenyl]-3,4,5-tris(ethyloxy)-benzamide (SANT-2) fully inhibited 3-chloro-4,7-difluoro-N-[trans-4-(methylamino)cyclohexyl]-N-{[3-(4-pyridinyl)phen yl]methyl}-1-benzothiophene-2-carboxamide (SAG-1.5)-induced Hh pathway activation. Detailed "Schild-type" radioligand binding analysis with [(3)H]SAG-1.3 revealed that two structurally distinct Smoothened receptor antagonists, SANT-1 and SANT-2, bound in a manner consistent with that of allosteric modulation. Our mechanism of action characterization of radioligand binding to Smo combined with functional data provides a better understanding of small-molecule interactions with Smo and their influence on the Hh pathway.